Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.46 |
| ▸ | HTR2B | P41595 | 6/20 | 0.42 |
| ▸ | HTR2A | P28223 | 5/20 | 0.42 |
| ▸ | PNMT | P11086 | 2/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18440305 | 1.00 | HTR2C (0.46) | HTR2CHTR2BHTR2APNMTASIC3 | |
| Trifluoroacetic Acid SCHEMBL18440399 | 0.88 | HTR2C (0.38) | HTR2CHTR2BHTR2A | |
| SCHEMBL29791577 | 0.82 | HTR2C (0.42) | HTR2CHTR2BHTR2APNMT | |
| SCHEMBL18440767 | 0.82 | HTR2A (0.47) | HTR2CHTR2BHTR2APNMT | |
| SCHEMBL29791587 | 0.82 | HTR2A (0.47) | HTR2CHTR2BHTR2APNMT | |
| SCHEMBL18440729 | 0.82 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| SCHEMBL29791595 | 0.82 | HTR2C (0.49) | HTR2CHTR2BHTR2A | |
| SCHEMBL18440756 | 0.82 | HTR2C (0.42) | HTR2CHTR2BHTR2APNMT | |
| SCHEMBL29791619 | 0.78 | HTR2C (0.46) | HTR2CHTR2BHTR2A | |
| SCHEMBL18440155 | 0.78 | HTR2C (0.46) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328835-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-12 | — | — | EP | claimed |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | HTR2C 1/4885HTR2B 4/4885HTR2A 2/4885 |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | HTR2C 1/4885HTR2B 4/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.